Although cancer chemotherapy has historically been considered immune suppressive, it is
now accepted that certain chemotherapies can augment tumor immunity. The recent …

Cancer immunotherapy is now established as a powerful way to treat cancer. The recent
clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) …

Immunotherapy is revolutionizing the management of multiple solid tumors, and early data
have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 …

Background Unresectable locally advanced or metastatic triple-negative (hormone-receptor–
negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is …

Background Immunotherapy in combination with chemotherapy has shown promising
efficacy across many different tumour types. We report the prespecified second interim …

Importance Atezolizumab (anti–programmed cell death ligand 1 [PD-L1]) is well tolerated
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple …

Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have
shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this …

Tumor-specific immune tolerance limits the effectiveness of cancer vaccines. In addition,
tumor vaccines alone have a limited potential for the treatment of measurable tumor …

A major barrier to successful antitumor vaccination is tolerance of high-avidity T cells specific
to tumor antigens. In keeping with this notion, HER-2/neu (neu)-targeted vaccines, which …

Background HER2-positive metastatic breast cancer is incurable and new treatments are
needed. Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer …